Who makes Blephamide?

Blephamide is developed by Joseph B. Ciolino, MD.

What development phase is Blephamide in?

Blephamide is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Blephamide

Joseph B. Ciolino, MD · FDA-approved active Small molecule

At a glance

Generic name	Blephamide
Also known as	sulfacetamide sodium 10%/prednisolone acetate 0.2%, Allergan, Inc.
Sponsor	Joseph B. Ciolino, MD
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases (NA)
Stereotactic Ablative Radiation Therapy for Prostate Cancer (NA)
Intraductal Meibomian Gland Probing Trial (PHASE4)
SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Blephamide CI brief — competitive landscape report
Blephamide updates RSS · CI watch RSS
Joseph B. Ciolino, MD portfolio CI